



At the forefront  
of telehealth &  
remote patient  
monitoring

## Company Presentation

# Company overview



G Medical is a mobile and e-health company that develops clinical grade solutions for professionals and consumers

Product suite includes proprietary devices, software solutions and patient service operations:

- **Prizma device** – consumer focused product that measures vital signs includes user portal and medical report
- **Prizma App** – multi-tiered (+freemium) application that encases users EMR
- **Web based portals** – online portal for both healthcare professionals and consumers
- **G Medical Patch** – Both VSMS and extended holter functionality (vital signs, cardiac diagnostics, Post-discharge)
- **Clinical portal** – continuous vital signs monitoring for enterprise providers
- **Remote patient monitoring (IDTF)** – through established 100% owned call centres in the USA

G Medical leverages patented wireless technologies, proprietary algorithms & information technology and service platforms to empower a new generation of consumers, patients and health care providers

**GMV improves the patient journey by:**



ENABLING EARLY  
DETECTION



IMPROVING HEALTHCARE  
OUTCOMES



REDUCING  
COSTS



EXPANDING ACCESS TO  
CLINICALLY RELEVANT  
INFORMATION

# Corporate snapshot



## Overview

ASX code	GMV
Shares on issue	561.9m
Options on issue	51m
Market capitalisation (\$0.11 per share)	~\$61.8m
52 week high - low	\$0.365 - \$0.038

## Board & management

Executive Director & CEO	Dr Yacov Geva
Non-executive Chairman	Dr Kenneth R Melani
Non-executive Director	Prof Zeev Rotstein
Non-executive Director	Dr Shuki Gleitman
Non-executive Director	Dr Brendan de Kauwe
Non-executive Director	Mr Urs Wettstein

## Major shareholders

## Percentage holding (%):

Dr Yacov Geva (direct and indirect)	52.48%
Acuity Capital Investment Management	3.29%
HSBC Custody Nominees	2.21%
Board & management	56.66%
Top 20	68.3%

## Price and volume April 2019 – April 2020



# Products and solutions

## Prizma device



- Built in sensors measure ECG, heart rate, SpO2, body temperature and stress
- Manual data entry of weight, glucose and blood pressure measurements
- Test, view and store measurements on a smartphone and on secure cloud portal
- Transmits all data to medical professionals on permissioning

## VSMS/GMP



- 6 channel ECG monitoring system that saves waveforms to SD card
- Allows for continuous monitoring of patients, outpatients after hospital discharge and cardiac monitoring
- Delivers real time, continuous data flow of heart rate, blood pressure, body temperature, ECG, body position and location
- All data is compiled and an extended clinical report is sent to hospital or physician

## Remote monitoring



- GMV monitors large volumes of patients through two remote monitoring and independent diagnostic testing facilities (IDTF)
- Year-on-year growth is 95% with ongoing uplift expected
- Subscription as a service model allows GMV to generate recurring revenue

# Summary of regulatory approvals

## Prizma device



- ✓ **USA:** FDA OTC and class 2 (510k) granted – includes all countries that accept FDA standards
- ✓ **Europe:** CE mark granted – includes all countries accepting CE standards
- ✓ **Australia & NZ:** Therapeutic Goods Administration (TGA) granted
- ✓ **Taiwan:** FDA granted – permit licence issued
- ⌚ **China:** NMPA approval in process

## VSMS/GMP



- ✓ **Europe:** CE mark granted – includes all countries accepting CE standards
- ⌚ **USA:** In application
- ⌚ **China:** In process
- ⌚ **Australia & NZ:** In application

## China manufacturing



- ✓ **Guangzhou manufacturing:** GMV has achieved CE, FDA and CFDA (now NMPA) regulatory approval granted for its production facility.

# Business model: products

## PRIZMA

### Sale of products:

- Prizma device and accessories

### Service fee income:



Cloud and portal access



Call Centre



Chronic Care Management

### Channels

#### B2B

- Insurance companies
- Medical institutions
- Distributors
- Government partners

#### B2C

- Online sales
- Market places



## VSMS/GMP

### Service fee income:

- Per patient use (daily)
- Prescription based cardiology services

### Sale of products

- Patch (per unit basis)
- Disposable accessories
- Enterprise software platform


### Channels

#### B2B

- Hospitals and clinics
- Remote or outpatient monitoring
- Physicians

## PATIENTS' HEALTHCARE LIFECYCLE

# Business model: IDTF & remote patient monitoring



## INCOME BASED ON SERVICE TYPE

Extended Holter (AECG)

Mobile Cardiac Telemetry (MCT)

Cardiac Event Monitoring (CEM)



# Peer comparison

## NASDAQ listed competition



Company name	Code	Description	Market cap	Revenue	Net income
Biotelemetry Inc	BEAT	Provides ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. Focused on diagnosis and monitoring of cardiac arrhythmias, and heart rhythm disorders.	US\$1,778m	US\$399m	US\$42.82m
Irhythm Technologies Inc	IRTC	Develops, produces, and distributes medical instruments, offers cardiac rhythm monitoring devices for palpitation, shortness of breath and fatigue.	US\$2,359m	US\$147m	-US\$48.28



# Recent progress made on a global scale

## USA:

- Prizma device granted over-the-counter approval by FDA – device can now be bought by consumers without a prescription
- Distribution agreement secured with LiveCare to integrate Prizma into Life+ remote patient monitoring platform
- Planning for NASDAQ IPO underway – financial and listing advisors appointed – includes Fosun Hani, investment arm of Chinese conglomerate Fosun Group

## Italy:

- Prizma successfully registered with Italy's Ministry of Health
- First shipment of devices sent to in country distribution partner, Meditel

## Taiwan & China:

- Taiwan FDA approval granted for Prizma device – market entry pending with in country partner First Channel Limited
- NMPA approval for Prizma device pending in China – all clinical trials finalised with approval expected H2 2020

## Australia:

- Agreement with HomeStay Care (ASX: HSC) to integrate Prizma into uVue telehealth offering

# Key market focus: USA

Recent progress in the USA has laid a strong foundation for growth



## Over-the-counter (OTC) approval secured for the Prizma device:

- Approval allows for Prizma to be sold over-the-counter to consumers without a prescription
- Authorisation was granted on FDA's 'Policy for COVID-19 Public Health Emergency
- GMV exploring multiple sales avenues including direct to consumers launch, distribution agreements with large retail outlets, referral agreements from medical organisations



## Distribution agreement with LiveCare:

- Agreement to distribute and integrate Prizma into LiveCare's Life+ platform
- Life+ is a smart home gateway that integrates medical devices into users homes creating a leading remote patient monitoring solution
- Following the COVID-19 pandemic, LiveCare became the preferred provider to the Independent Physicians Association of America which represents 700 organisations in 39 states and over 300,000 physicians and affiliates
- Provides G Medical direct access to an established, addressable market in the USA

# : Key market focus: USA



## : Remote Patient Monitoring and CPT codes

GMV's diagnostic services provide a complete remote patient monitoring solution. RNs and certified clinical analyse incoming patient generated health data, notify for abnormal events, and generate patient data into concise reports.

Clinics utilising GMV solutions bill using CMS-approved codes for remote patient monitoring:

CPT code	Descriptor
99453	Remote monitoring of physiologic parameter(s) initial; set-up and patient education on use of equipment.  <b>Average one-time Medicare payment of US\$21</b>
99454	Remote monitoring of of physiologic parameter(s)initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each thirty days.  <b>Average monthly Medical payment of US\$69</b>
99457	Remote physiologic monitoring treatment management services, 20 minutes or more of clinical staff/physician/other qualified healthcare professional time in a month requiring interactive communication with patient/caregiver during month.  <b>Average monthly Medicare payment of US\$54</b>

**RPM services can be delivered by clinical staff of the billing provider. For example, RNs and medical assistants (subject to state law and supervision requirements). This allows patients to be anywhere, even in the home.**

**Part B Medicare 20% co-pay applies.**

# Key market focus: USA

Potential NASDAQ IPO to unlock additional shareholder value



## Planned NASDAQ IPO:

- GMV is considering a potential NASDAQ IPO in Q3 2020
- Company is confident that it would provide added exposure to a larger pool of investors and underpin a potentially higher valuation
- IPO is dependent on market conditions and GMV can give no guarantee to its certainty

## Financial and Listing Advisors appointed to progress US listing:

- Fosun Hani and Boustead Securities appointed as listing and financial advisors
- Fosun Hani Securities is the 100% owned investment arm of Chinese conglomerate and investment company of Fosun Group
- Fosun Group has a superior track record in growing businesses across a range of sectors – particular success in healthcare companies
- Boustead is a leading investment banking firm based in California specialising in IPO's, M&A and capital raising initiatives
- Both parties bring extensive experience and investor relationships to the company



# Key market focus: Italy

Distribution agreements and approvals unlock a significant opportunity



## **Prizma device successfully registered with Italian Ministry of Health:**

- Prizma registered with Italian Ministry of Health's database of medical products
- Prizma has previously received CE mark for use in Europe – no barriers for market entry
- Italy is a prime example of a healthcare system under pressure - GMV is confident that Prizma can assist in alleviating pressure on healthcare systems facing capacity challenges
- Allows G Medical to aggressively pursue first European market entry



## **Distribution agreement with Meditel expedites market entry:**

- Meditel is a leading European telemedicine provider
- Distribution agreement covers both Prizma device and Extended Holter product
- Meditel has developed the Lifechart platform to home monitor chronic patients – web based platform was designed to defray costs for hospitals and healthcare facilities
- Meditel has over 500 telemedicine service points in pharmacies across Italy – providing an established channel for GMV product integration

# Key market focus: Australia

Agreements and endorsements in Australia validate product offering



## **Agreement with HomeStay Care (ASX: HSC) to integrate Prizma in uVue:**

- uVue is HSC's cloud based telehealth solution utilised by aged care homes in Australia and New Zealand
- Platform connects to a seniors television and provides entertainment, messaging capabilities, calendar and healthcare solutions
- uVue is used by a large number of aged care providers that have challenges effectively communicating with the elderly due to the technology gap experienced by seniors
- Prizma will now appear on the uVue TV application allowing caers to prompt residents to measure vital signs – data will be sent automatically to the cloud
- Should there be any adverse readings detected the resident will be triaged by a 24-hour response service to provide proactive care

---

## **Multiple in country opportunities pending:**

- Ongoing discussions with key industry bodies
- Potential distribution agreements
- Marketing and product sales initiatives

# Key market focus: Australia



## Telehealth initiative provides opportunity for GMV

Rebates for telehealth services are the same as those paid for equivalent face-to-face services with a doctor, physician or healthcare professional. Medicare Benefits Schedule (MBS) has introduced an array of Telehealth related Item Numbers. These are applicable if:

- Healthcare professionals can provide full service through these means safely and in accordance with professional standards
- Doctors and physicians are satisfied that it is clinically appropriate to provide the service to the patient
- A visual and audio link is maintained with the patient
- The software and hardware used to deliver the service meets applicable laws for security and privacy

**Rebate Examples:** (Full list can be found via the [MBSonline.gov.au](https://www.mbsonline.gov.au) website)

Item number	Descriptor	Rebate
91790	Telehealth attendance by a general practitioner for an obvious problem characterised by the straightforward nature of the task that requires a short patient history and, if required, limited management.	\$17.50
91800	Telehealth attendance by a general practitioner lasting less than 20 minutes if the attendance includes any of the following that are clinically relevant: a) taking a short patient history; b) arranging any necessary investigation; c) implementing a management plan; and d) providing appropriate preventative health care.	\$38.20
91801	Telehealth attendance by a general practitioner lasting at least 20 minutes if the attendance includes any of the following that are clinically relevant a) Taking a detailed patient history; b) arranging any necessary investigation; c) implementing a management plan; and d) providing appropriate preventative health care.	\$73.95
91802	Telehealth attendance by a general practitioner lasting at least 40 minutes if the attendance includes any of the following that are clinically relevant: a) Taking an extensive patient history; b) arranging any necessary investigation; c) Implementing a management plan; and d) providing appropriate preventative health care.	\$108.85



# Key market focus: China & Taiwan

China and Taiwan provide massive opportunities



**All relevant information provided for NMPA (formerly CFDA) approval of Prizma (currently in progress):**

- Recently completed clinical trials with Prizma device on 208 patients across multiple hospitals in China
- Clinical trials finalised for National Medical Products Administration approval
- NMPA approval will unlock G Medical's China entry – underpinning a considerable opportunity



**Taiwan FDA approval granted for Prizma – market entry progressing:**

- Approval from Taiwan FDA and receipt of permit licence allows GMV to progress Taiwan market entry
- Commercial negotiations are underway with existing non-exclusive partners in the country
- GMV delineating commercial strategies for market entry – multiple sales channels being explored
- Additional partnerships being pursued to expedite sales and product uptake

# · Near term growth drivers

· GMV has a number of value catalysts pending

## **Product uptake in Italy**

First shipments of Prizma to be delivered in near term with sales growth expected shortly after

## **NASDAQ IPO initiatives**

Investor focused roadshows, promotional events and subsequent listing expected

## **Broadening global footprint**

GMV to pursue additional international market entries where applicable

## **Additional US distribution agreements**

GMV is progressing discussions with multiple parties to sell and promote the Prizma in the USA

## **VSMS approvals**

GMV pursuing FDA (US) and TGA (Australia) regulatory approvals for the "PATCH"

## **NMPA approval**

Unlocks China market entry – provides large potential for GMV

# Established global footprint

## Australia:

- Primary listing exchange (ASX)
- Distribution agreements in place

## Israel:

- R&D and regulatory

## USA:

- Remote patient monitoring
- Medical device sales
- OTCQB listing (GMMVF)
- Proposed NASDAQ IPO

## China:

- Manufacturing through NMPA, CE and FDA approved production facility

## Hong Kong:

- Business sales hub

## Italy:

- Device sales
- Remote patient monitoring pending

## Macedonia:

- Additional technical R&D



# Contact:

## Executive Director & CEO:

Dr Yacov Geva  
E: [yacovg@gmedinnovations.com](mailto:yacovg@gmedinnovations.com)  
W: [www.gmedinnovations.com](http://www.gmedinnovations.com)

## Director & Corporate Development:

Dr Brendan de Kauwe  
E: [brendan@gmedinnovations.com](mailto:brendan@gmedinnovations.com)

## Investor enquiries:

Henry Jordan  
E: [henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)  
M: +61 (0) 431 271 538



## G Medical Innovations Holdings Ltd Cayman Islands

P.O. Box 10008, Willow House, Cricket Square  
Grand Cayman, KY1-1001, Cayman Islands

c/o  
G Medical Diagnostic Services, Inc.  
1500 Lakeside Dr. Ste 115  
Bannockburn, IL 60015 USA

# Appendix 1: Management overview



## An established track record in medical device commercialisation

### Dr. Kenneth R. Melani

#### Chairman of the Board

Dr. Melani has over 30 years' experience in the healthcare industry as a provider, supplier and insurer. He has started seven successful for-profit health services businesses and has served in various critical business roles including CEO, Chief Medical Office, and Strategy and Business Development.

During his tenure as President and CEO of Highmark Inc. in 2003 to 2012, he grew the company into one of the largest and most diversified healthcare companies in the United States, serving over 32 million individuals. He has been an investor in numerous pre- IPO investments since 1985 and was instrumental for several successful IPOs in Switzerland.

### Dr. Yacov Geva

#### Managing Director & CEO

A well-known pioneer in the industry of Medical Devices and remote monitoring services, and co-founder of LifeWatch AG (former Card Guard AG and Card Guard Scientific Survival Ltd.). Successfully led LifeWatch to an IPO. Dr. Geva holds a B.Sc in Mechanical and Nuclear Engineering, a Ph.D. (with honors) in Business Administration from the International School of Management, Paris and an honorary doctorate from Oxford Brooks University. Dr. Geva is also a senior member of the royal society of medicine in the UK (RSM).

### Mr. Rafi Heumann

#### President & COO

Mr. Heumann has over 20 years of experience in Hi-tech, mHealth, operations and services industries. He brings with him advanced skills in strategic planning, international negotiations and business development, and directing complex projects. Mr. Heumann has business management education from Bar-Ilan University, Israel.

### Dr. Brendan de Kauwe

#### Director & Corporate Development

Dr de Kauwe studied a Bachelor of Science and a Bachelor of Dental Surgery at the University of Western Australia, with Post Graduate certifications in Oral Surgery and Implantology. He also holds a Post Graduate Diploma in Applied Finance, majoring in Corporate Finance. Dr de Kauwe is an experienced operations and transaction focused executive with key skills in creating company value through strategic partnerships and mergers and acquisitions. He has vast experience in public market transactions and equity capital markets in both Australia and internationally. He has served as Chairman and/or Director of numerous ASX listed companies. in the life sciences and technology sectors.

### Mr. Benny Tal

#### VP, R&D

Mr. Tal brings over 40 years of expertise in Electronics Development, Engineering and Operations. He has led R&D, engineering, and operation teams for OEM/ODM products. Mr. Tal holds a B.Sc. in Electrical Engineering and Computers and an MBA from Ben-Gurion University, Israel.

### Mr. Nir Geva

#### CTO

Mr. Geva has over 17 years of experience in the Hi-Tech and Medical Device industry. A former CTO and strategic projects manager at LifeWatch Technologies, he has broad knowledge on project management and manufacturing of medical devices. Mr. Geva wrote over 15 patents related to Medical Devices, Remote Patients Monitoring and IoT. He holds a BSc. in Mechanical Engineering from the Technion in Haifa and an Executive MBA from Kellogg school of management, (Northwestern University in Chicago).

### Mr. Kobi Ben-Efraim

#### CFO

An experienced and senior CFO of global companies with more than 20 years' experience in the finance and accounting domain. He has served in Israeli high tech companies including DSPC Group (a NASDAQ-traded company) and El-Op. Mr. Ben-Efraim holds a B.A. in Economics and Accounting from Tel Aviv University, and is a Certified Public Accountant (IL).

# Appendix 2: Management experience

Significant experience in all facets of connected care




## Strong R&D

- Over 25 years of experience in developing mobile embedded medical sensors



## Regulatory approvals

- Medical grade devices – approved following FDA and CE guidance
- Over 48 medical devices approved by FDA



## Go To Market

- Over 25 years of medical device development and commercialization



## Medical Service Model – Medical Call Centers setup and operation

- *Over 25 years of experience in international and US patients monitoring*
- *Over 5M patients monitored*


# Appendix 3: Prizma functionality

## prizma G2

Built-in sensors measure ECG, Heart rate, SpO<sub>2</sub>, body temperature and stress

Manual data entry of weight, glucose and blood pressure measurements

Test, view and store measurements on your smartphone and on secure Cloud portal





# Appendix 4: Prizma personal medical portal

- Provides test results, charts, user settings, tutorials and support



- Home
- ECG
- Temperature
- SpO2
- Heart Rate
- Stress
- Blood Pressure
- Body Weight
- Glucose Level
- Settings
- Reminders
- Videos and tutorials
- Log Out

prizma **G2**

Help | My Services | Support | Online Store

Report

## Welcome to your Personal Medical Portal

You are now ready to start taking your tests

ECG

**Last 5 Tests**

75bpm	Sep 11th, 9:30 am
77bpm	Sep 10th, 9:08 am
93bpm	Sep 7th, 11:40 am
76bpm	Sep 6th, 12:38 pm
85bpm	Sep 4th, 8:22 am

Heart Rate

**Last 5 Tests**

78bpm	Sep 11th, 9:38 am
76bpm	Sep 10th, 9:11 am
90bpm	Sep 7th, 11:43 am
74bpm	Sep 6th, 12:41 pm
86bpm	Sep 4th, 8:25 am

SpO2

**Last 5 Tests**

95%	Sep 11th, 9:37 am
98%	Sep 10th, 9:10 am
98%	Sep 7th, 11:42 am
93%	Sep 7th, 11:42 am
96%	Sep 6th, 12:41 pm

Temperature

**Last 5 Tests**

37.5°C	Sep 11th, 9:37 am
37.5°C	Sep 10th, 9:09 am
37.5°C	Sep 7th, 11:41 am
37.7°C	Sep 6th, 12:40 pm
38.2°C	Sep 6th, 12:39 pm

Stress

**Last 5 Tests**

25ari	Sep 11th, 9:39 am
31ari	Sep 10th, 9:12 am
13ari	Sep 7th, 11:44 am
27ari	Sep 6th, 12:42 pm
13ari	Sep 4th, 8:26 am


Blood Pressure

**Last 5 Tests**

61/110mm/Hg	Sep 11th, 9:41 am
60/115mm/Hg	Sep 10th, 9:14 am
66/112mm/Hg	Sep 7th, 11:46 am
60/111mm/Hg	Sep 6th, 12:45 pm
66/115mm/Hg	Sep 4th, 8:28 am

# Appendix 5: Prizma doctor portal

Contains abnormal test results, medical history, physician comments etc.



# Appendix 6: Prizma medical report

Allows patient to share results with any third party from a phone or user portal



# Appendix 7: Patent status

AttorneyRef	Status	ApplicationNum	Patent Number	Title	Type	FilingDate	Grant Date	Inventors	
8968-US	Granted	15/026,258	10,251,603	SYSTEMS AND METHODS FOR VITAL SIGNS MONITORING WITH EAR PIECE	Non-Provisional	31/03/2016	09/04/2019	Nir Geva; Yacov Geva	
8967-US	Published	15/225,849		DEVICE, SYSTEM AND METHOD FOR NONINVASIVELY MONITORING PHYSIOLOGICAL PARAMETERS	Non-Provisional	02/08/2016		ir Geva; Yacov Geva; Rafi HEUMANN; Shiri CARMIELLI; Noam RACHELI; Nimrod ROSPSHA; Yaron CHEN; Tzur DI-CORI	
8967-BR	Pending	112017015881.7		Systems and methods for vital signs monitoring with ear piece	Brazil	25/07/2017		Nir Geva; Yacov Geva	
8967-JP	Pending	2017-557516		Systems and methods for vital signs monitoring with ear piece	Japan	25/07/2017		Nir Geva; Yacov Geva	
8967-KR	Pending	10-2017-7023630		Systems and methods for vital signs monitoring with ear piece	South Korea	25/07/2017		Nir Geva; Yacov Geva	
8968-CN	Pending	201680009360.5-cn		Device system and method for noninvasively monitoring physiological parameters	China	08/08/2017		Nir Geva; Yacov Geva	
8967-EP	Pending	16742887.9		Systems and methods for vital signs monitoring with ear piece	China / EPO	10/08/2017		Nir Geva; Yacov Geva	
8947-PC	Pending	PCT/IL2017/050939		JACKET FOR MEDICAL MODULE	PCT	22/08/2017		Nir Geva	
8967-RU	Pending	2017124408		Systems and methods for vital signs monitoring with ear piece	Russia	12/10/2017		Nir Geva; Yacov Geva	
8968-AU	Pending	2016303577		Device system and method for noninvasively monitoring physiological parameters	Australia	18/11/2017		Nir Geva; Yacov Geva	
8968-EP	Pending	16832414.3		Device system and method for noninvasively monitoring physiological parameters	EPO	29/01/2018		Nir Geva; Yacov Geva	
8968-JP	Pending	JP2018-505477		Device system and method for noninvasively monitoring physiological parameters	Japan	29/01/2018		Nir Geva; Yacov Geva	
8947-CN	Granted	201790000342-cn		JACKET FOR MEDICAL MODULE	China	30/01/2018	01/06/2019	Nir Geva	
9093-CN	Granted	201820157683.5-cn		HEALTH MONITORING DEVICE THAT INCLUDES A COMPACT OXIMETER	China	30/01/2018	01/06/2019	Yacov Geva; Nir Geva	
8968-BR	Pending	BR 11 2018 002219-5		Device system and method for noninvasively monitoring physiological parameters	Brazil	01/02/2018		Nir Geva; Yacov Geva	
8981-PC	Pending	PCT/IL2018/050146		METHOD AND SYSTEM FOR LOCATING A DEFIBRILLATOR	PCT	08/02/2018		Nir Geva; Zeev Rotstein	
8968-KR	Pending	10-2018-7006193		Device system and method for noninvasively monitoring physiological parameters	South Korea	02/03/2018		Nir Geva; Yacov Geva	
8968-RU	Pending	2018105962		Device system and method for noninvasively monitoring physiological parameters	Russia	02/03/2018		Nir Geva; Yacov Geva	
9093-PC	Pending	PCT/IB2018/058879		HEALTH MONITORING DEVICE THAT INCLUDES A COMPACT OXIMETER	PCT	12/11/2018		Yacov Geva; Nir Geva	
9046-PC	Pending	PCT/IB2018/057354		METHOD AND SYSTEM FOR OBTAINING PHYSICAL CONDITION THAT LEAD TO A DEFIBRILLATOR CONUTERSHOCK	PCT	24/09/2018		Nir Geva; Ilya Litovchick	
8968-US1	Pending	16/362,662		SYSTEMS AND METHODS FOR VITAL SIGNS MONITORING WITH EAR PIECE	Non-Provisional	3/24/2019		Nir Geva; Yacov Geva	
9189-PC	Pending	PCT/IB2019/053561		A ROBUST MEDICAL DEVICE AND METHOD	PCT	01/05/2019		Nir Geva	
9364-USP	Pending	62/848,666		Weight scale	Provisional	16/05/2019		Nir Geva	
8953-US	Pending	16/344,022		REMOTE MONITORING OF A PERSON AND AN AUTOMATIC DISTRIBUTION OF PRESCRIPTION DRUGS	Non-Provisional	23/04/2019		Nir Geva	
8953-EP	Pending			REMOTE MONITORING OF A PERSON AND AN AUTOMATIC DISTRIBUTION OF PRESCRIPTION DRUGS	EPO	17/05/2019		Nir Geva	
8953-BR	Pending	BR 11 2019 008294-8		REMOTE MONITORING OF A PERSON AND AN AUTOMATIC DISTRIBUTION OF PRESCRIPTION DRUGS	Brazil	24/04/2019		Nir Geva	
8953-JP	Pending			REMOTE MONITORING OF A PERSON AND AN AUTOMATIC DISTRIBUTION OF PRESCRIPTION DRUGS	Japan	24/04/2019		Nir Geva	
8947-EP	Pending	17843061.7		JACKET FOR MEDICAL MODULE	EPO	12/04/2019		Nir Geva	
8947-JP	Pending	2019-511429		JACKET FOR MEDICAL MODULE	Japan	20/02/2019		Nir Geva	
8947-BR	Pending	BR 11 2019 003393.9		JACKET FOR MEDICAL MODULE	Brazil	20/02/2019		Nir Geva	



# Appendix 8: VSMS Patch – additional background


## Beat to beat recording of multichannel ECG

Continuously (beat to beat) records a multi-channel (6 leads) ECG and saves the waveforms to SD card. At the end of monitoring service a comprehensive clinical report is provided to the physician.

### Lead I, lead II, lead III, aVL, aVF, and aVR



- Single device with comfortable format enhances patient compliance – no wires or extra equipment
- Enhanced patient compliance results in more data that increases diagnostic yields
- IP (or "Ingress Protection") rating allows daily showering
- Manual "event" button allows patient to mark a suspected cardiac event



# Disclaimer

## NOT AN OFFER OF SECURITIES

This document has been independently prepared by G Medical Innovations Holdings Ltd (GMV) and is provided for informational purposes only.

This document does not constitute or contain an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in GMV. This document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction (in particular, the United States), or a securities recommendation. This document is not a prospectus, product disclosure statement or other offering document under Australian law or any other law, and will not be lodged with the Australian Securities and Investments Commission.

### Summary information

This document contains a summary of information about GMV and its activities that is current as at the date of this document. The information in this document is general in nature and does not purport to be complete or to contain all the information which a prospective investor may require in evaluating a possible investment in GMV or that would be required in a prospectus or a product disclosure statement prepared in accordance with the Corporations Act 2001 (Cth) (Corporations Act).

## No liability

The information contained in this document has been prepared in good faith by GMV, however no guarantee representation or warranty expressed or implied is or will be made by any person (including GMV and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document. To the maximum extent permitted by law, GMV and its affiliates and their directors, officers employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice. No responsibility or liability is assumed by GMV or any of its affiliates for updating any information in this document or to inform any recipient of any new or more accurate information or any errors or mis-descriptions of which GMV and any of its affiliates or advisers may become aware.

## Forward looking statement

Certain information in this document refers to the intentions of GMV, but these are not intended to be forecasts, forward looking statements or statements about the future matters for the purposes of the Corporations Act or any other applicable law. The occurrence of the events in the future are subject to risk, uncertainties and other actions that may cause GMV's actual results, performance or achievements to differ from those referred to in this document. Accordingly GMV and its affiliates and their directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of these events referred to in the document will actually occur as contemplated.

Statements contained in this document, including but not limited to those regarding the possible or assumed future costs, performance, dividends, returns, revenue, exchange rates, potential growth of GMV, industry growth or other projections and any estimated company earnings are or may be forward looking statements. Forward-looking statements can generally be identified by the use of words such as 'project', 'foresee', 'plan', 'expect', 'aim', 'intend', 'anticipate', 'believe', 'estimate', 'may', 'should', 'will' or similar expressions. These statements relate to future events and expectations and as such involve known and unknown risks and significant uncertainties, many of which are outside the control of GMV. Actual results, performance, actions and developments of GMV may differ materially from those expressed or implied by the forward-looking statements in this document.

Such forward-looking statements speak only as of the date of this document. There can be no assurance that actual outcomes will not differ materially from these statements. To the maximum extent permitted by law, GMV and any of its affiliates and their directors, officers, employees, agents, associates and advisers:

- disclaim any obligations or undertaking to release any updates or revisions to the information to reflect any change in expectations or assumptions;
- do not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this document, or likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement; and
- disclaim all responsibility and liability for these forward-looking statements (including, without limitation, liability for negligence).

## Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product.

An investment in GMV is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

## Information in this document is confidential

This document and the information contained within it are strictly confidential and are intended for the exclusive benefit of the persons to whom it is given. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of GMV. By receiving this document, you agree to keep the information confidential, not to disclose any of the information contained in this document to any other person and not to copy, use, publish, record or reproduce the information in this document without the prior written consent of GMV, which may be withheld in its absolute discretion.

## Acceptance

By attending an investor presentation or briefing, or accepting, accessing or reviewing this document you acknowledge and agree to the "Disclaimer" as detailed above.